Comparative Pharmacology
Head-to-head clinical analysis: TECVAYLI versus XTANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TECVAYLI versus XTANDI.
TECVAYLI vs XTANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bispecific T-cell engager antibody that binds to BCMA on multiple myeloma cells and CD3 on T-cells, leading to T-cell activation and targeted cytotoxicity.
Androgen receptor inhibitor; binds to the androgen receptor, inhibits nuclear translocation, DNA binding, and transcription of androgen-responsive genes.
Subcutaneous injection: Step-up dosing schedule. First dose 0.06 mg/kg, then 0.3 mg/kg on day 4, followed by 1.5 mg/kg weekly starting day 7. Maximum single dose 1.5 mg/kg.
160 mg orally once daily.
None Documented
None Documented
22.5 days (range 10–35 days) based on population pharmacokinetic analysis; supports every-2-week dosing after step-up.
Enzalutamide: 5.8 days; active metabolite N-desmethyl enzalutamide: 7.8-8.6 days. Steady state achieved after ~28 days.
Primarily catabolized to small peptides and amino acids; not expected to be excreted renally or hepatically to a significant extent.
Primarily hepatic metabolism; 77% of dose recovered in feces (as metabolites), 15% in urine (as metabolites); less than 1% excreted unchanged.
Category C
Category C
Antineoplastic
Antineoplastic